Regenxbio Q3 2023 Gaap EPS $(1.41) Beats $(1.49) Estimate, Sales $28.91M Beat $27.19M Estimate
Portfolio Pulse from saritha@benzinga.com
Regenxbio reported Q3 2023 GAAP EPS of $(1.41), beating the estimate of $(1.49) by 5.37%. This is a 19.43% increase over the same period last year. The company also reported sales of $28.91M, beating the estimate of $27.19M by 6.34%, a 9.06% increase from last year.
November 08, 2023 | 9:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Regenxbio's Q3 2023 results beat estimates, with an increase in EPS and sales compared to the same period last year.
Regenxbio's better-than-expected Q3 2023 results, with an increase in both EPS and sales compared to the same period last year, could positively impact the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100